Cargando…
Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases
The effects of interstitial lung disease (ILD) create a significant burden on patients, unsettling almost every domain of their lives, disrupting their physical and emotional well-being and impairing their quality of life (QoL). Because many ILDs are incurable, and there are limited reliably-effecti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489034/ https://www.ncbi.nlm.nih.gov/pubmed/30578334 http://dx.doi.org/10.1183/16000617.0075-2018 |
_version_ | 1784792791931420672 |
---|---|
author | Swigris, Jeffrey J. Brown, Kevin K. Abdulqawi, Rayid Buch, Ketan Dilling, Daniel F. Koschel, Dirk Thavarajah, Krishna Tomic, Rade Inoue, Yoshikazu |
author_facet | Swigris, Jeffrey J. Brown, Kevin K. Abdulqawi, Rayid Buch, Ketan Dilling, Daniel F. Koschel, Dirk Thavarajah, Krishna Tomic, Rade Inoue, Yoshikazu |
author_sort | Swigris, Jeffrey J. |
collection | PubMed |
description | The effects of interstitial lung disease (ILD) create a significant burden on patients, unsettling almost every domain of their lives, disrupting their physical and emotional well-being and impairing their quality of life (QoL). Because many ILDs are incurable, and there are limited reliably-effective, life-prolonging treatment options available, the focus of many therapeutic interventions has been on improving or maintaining how patients with ILD feel and function, and by extension, their QoL. Such patient-centred outcomes are best assessed by patients themselves through tools that capture their perceptions, which inherently incorporate their values and judgements. These patient-reported outcome measures (PROs) can be used to assess an array of constructs affected by a disease or the interventions implemented to treat it. Here, we review the impact of ILD that may present with a progressive-fibrosing phenotype on patients' lives and examine how PROs have been used to measure that impact and the effectiveness of therapeutic interventions. |
format | Online Article Text |
id | pubmed-9489034 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-94890342022-11-14 Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases Swigris, Jeffrey J. Brown, Kevin K. Abdulqawi, Rayid Buch, Ketan Dilling, Daniel F. Koschel, Dirk Thavarajah, Krishna Tomic, Rade Inoue, Yoshikazu Eur Respir Rev Review The effects of interstitial lung disease (ILD) create a significant burden on patients, unsettling almost every domain of their lives, disrupting their physical and emotional well-being and impairing their quality of life (QoL). Because many ILDs are incurable, and there are limited reliably-effective, life-prolonging treatment options available, the focus of many therapeutic interventions has been on improving or maintaining how patients with ILD feel and function, and by extension, their QoL. Such patient-centred outcomes are best assessed by patients themselves through tools that capture their perceptions, which inherently incorporate their values and judgements. These patient-reported outcome measures (PROs) can be used to assess an array of constructs affected by a disease or the interventions implemented to treat it. Here, we review the impact of ILD that may present with a progressive-fibrosing phenotype on patients' lives and examine how PROs have been used to measure that impact and the effectiveness of therapeutic interventions. European Respiratory Society 2018-12-21 /pmc/articles/PMC9489034/ /pubmed/30578334 http://dx.doi.org/10.1183/16000617.0075-2018 Text en Copyright ©ERS 2018. https://creativecommons.org/licenses/by-nc/4.0/ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Review Swigris, Jeffrey J. Brown, Kevin K. Abdulqawi, Rayid Buch, Ketan Dilling, Daniel F. Koschel, Dirk Thavarajah, Krishna Tomic, Rade Inoue, Yoshikazu Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases |
title | Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases |
title_full | Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases |
title_fullStr | Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases |
title_full_unstemmed | Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases |
title_short | Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases |
title_sort | patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489034/ https://www.ncbi.nlm.nih.gov/pubmed/30578334 http://dx.doi.org/10.1183/16000617.0075-2018 |
work_keys_str_mv | AT swigrisjeffreyj patientsperceptionsandpatientreportedoutcomesinprogressivefibrosinginterstitiallungdiseases AT brownkevink patientsperceptionsandpatientreportedoutcomesinprogressivefibrosinginterstitiallungdiseases AT abdulqawirayid patientsperceptionsandpatientreportedoutcomesinprogressivefibrosinginterstitiallungdiseases AT buchketan patientsperceptionsandpatientreportedoutcomesinprogressivefibrosinginterstitiallungdiseases AT dillingdanielf patientsperceptionsandpatientreportedoutcomesinprogressivefibrosinginterstitiallungdiseases AT koscheldirk patientsperceptionsandpatientreportedoutcomesinprogressivefibrosinginterstitiallungdiseases AT thavarajahkrishna patientsperceptionsandpatientreportedoutcomesinprogressivefibrosinginterstitiallungdiseases AT tomicrade patientsperceptionsandpatientreportedoutcomesinprogressivefibrosinginterstitiallungdiseases AT inoueyoshikazu patientsperceptionsandpatientreportedoutcomesinprogressivefibrosinginterstitiallungdiseases |